Wikipedia -WSS

Wikipedia

author：hotspot 2025-10-02 11:10:15 - browse：27

Maze Therapeutics CEO Jason Coloma Courtesy

After seeing its last deal go bust in the face of regulatory scrutiny, Maze Therapeutics has found another suitor for its experimental Pompe disease treatment.

Bay Area-based Maze and Shionogi said Friday that the Japanese pharma company had licensed the drug, called MZE001, with an upfront payment of $150 million. The global deal includes additional, undisclosed payments if the oral medication, which is in clinical testing, meets certain regulatory and commercial goals.

Last year, Sanofi, the French pharma giant, was set to pay $150 million in cash and stock to Maze before the transaction fell apart.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： New air purifier tech could be key to improving indoor air quality
Next article： Cognito secures funding to test medical device for Alzheimer's

WSS

General Catalyst, Summa Health deal will turn on physician buy

Some dementia cases could be undiagnosed liver disease

Medicare drug price negotiation’s day in court

Patients, doctors press FTC to beef up hospital merger scrutiny

Congressmen charge Covid hearing ‘could have been an email’

Grad students accuse University of California of wage theft

knowledge

Wikipedia

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

hotspot

Heart attack and stroke risk calculators need revising

Free Covid tests will again be offered to all U.S. households

Drug repurposing or repositioning? The language matters

Covid misinformation case heads to Supreme Court

ChatGPT in medicine: STAT answers readers' burning questions

New Ultima Genomics DNA sequencer can read genome for $100

Medicare proposal to cover medical devices draws a mixed reaction

Why the quest to eradicate polio has stumbled

Malaria cases in Florida and Texas: Here’s what you need to know

Eli Lilly CEO gives to Mike Pence presidential super PAC

focus

General Catalyst, Summa Health deal will turn on physician buy

Time to name cancers by genetics, not organ of origin, expert says

Bankrupt Pear's prescription app helped MassHealth save money, data suggests

Chamber of Commerce, DOJ clash in court over drug prices

Neurocrine congenital adrenal hyperplasia trial succeeds

Do digital therapeutics have a future in medicine?

focus

leisure time

explore

focus